Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial - Dhainaut, JF; Laterre, PF; Janes, JM (Intensive Care Med, 2003)
et al.